WorldCat Identities

Wysokinski, Waldemar E.

Overview
Works: 10 works in 10 publications in 1 language and 17 library holdings
Roles: Other, Contributor
Publication Timeline
.
Most widely held works by Waldemar E Wysokinski
Clinical and echocardiographic measures governing thromboembolism destination in atrial fibrillation( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin by Damon E Houghton( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Platelet factor XIII gene expression and embolic propensity in atrial fibrillation( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation by Kevin P Cohoon( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Apixaban and dalteparin in active malignancy associated venous thromboembolism The ADAM VTE Trial( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Antithrombotic Action of Endogenous Porcine Protein C Activated with a Latent Porcine Thrombin Preparation( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

The impact of gender and left atrial blood stasis on adiponectin levels in non-valvular atrial fibrillation( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract: Background: Obesity is a risk factor for non-valvular atrial fibrillation (NVAF), diabetes mellitus, and hypertension. Adiponectin, a unique biomarker of adipose tissue, has antiinflammatory, insulin-sensitizing, and antiatherogenic properties and is known to be higher in women. The relationship between adiponectin, gender, and thromboembolic risk in atrial fibrillation however is unknown. Methods: The relationship between gender, adiponectin levels, and echocardiographic measures of blood stagnation and left atrial appendage thrombus (LAAT) was assessed in 209 patients with NVAF (55 women and 154 men; mean age 63 ± 14 years) compared to 70 normal sinus rhythm controls (29 women and 41 men; mean age 64 ± 14 years). Total adiponectin was measured by solid-phase ELISA. Demographic and clinical variables of CHADS2 and CHA2DS2-VASc were collected, and spontaneous echocardiographic contrast (SEC), left atrial appendage emptying velocity (LAAEV) and left atrium volume index (LAVI) were measured prospectively. Results: Elevated adiponectin was associated with advanced cardiovascular pathology and permanent arrhythmia but only in men with NVAF. In NVAF men, a step-wise increase in adiponectin levels was noted relative to increasing intensity of SEC and decreasing LAAEV. Adiponectin level> 16657 ng/ml predicted LAAT (OR: 3.66; 95% Cl: 1.21-11.48; p = 0.022) after adjustment for CHADS2 score in men but not in women with NVAF. Conclusions: There is a direct correlation between elevated adiponectin level and the degree of left atrial blood stasis in men but not in women with NVAF. High adiponectin levels can be used as an important variable in the prediction of LAAT
Ovarian Vein Thrombosis( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : OBJECTIVE: To identify the risk of venous thromboembolism recurrence, major bleeding, and mortality in patients with ovarian vein thrombosis so as to better define optimal treatment strategies. METHODS: Patients with ovarian vein thrombosis (1990-2015) and age- and gender-matched patients with contemporary leg deep vein thrombosis (DVT) were assessed for differences in etiology, venous thromboembolism recurrence, and survival in a case-control study. RESULTS: Over the timeframe of this study, only 219 ovarian vein thrombosis cases were identified compared with 13, 417 leg DVTs. Median duration of follow-up was 1.23 years (interquartile range 0.25-4.14). Pulmonary embolism was identified at presentation in 6% of patients with ovarian vein thrombosis and 16% of those with DVT (P =.001). Frequent causes of ovarian vein thrombosis included cancer, hormonal stimulation, surgery, and hospitalization. Cancer was twofold more frequent in patients with ovarian vein thrombosis (44% compared with 21%; P <.01). Despite being less frequently treated with anticoagulation (ovarian vein thrombosis 54% compared with DVT 98%, P <.001), venous thromboembolism recurrence rates were similar between groups (ovarian vein thrombosis 2.3 compared with DVT 1.8 per 100 patient-years, P =.49). A personal history of venous thromboembolism and preceding surgery was found to be an independent risk factor for venous thromboembolism recurrence among those treated with anticoagulation (hazard ratio 6.7, P =.04 and hazard ratio 13.6, P =.03, respectively). There was no significant difference in overall survival. CONCLUSION: Ovarian vein thrombosis is a rare thrombotic condition with an incidence 60-fold lower compared with leg DVT in our institution. The striking association with cancer adversely affects overall survival rates in patients with ovarian vein thrombosis. Venous thromboembolism recurrence rates argue for anticoagulation with a direct oral anticoagulant or vitamin K antagonist, particularly in those with a history of venous thromboembolism. Abstract : Ovarian vein thrombosis is a rare thrombotic condition with a striking association with cancer and venous thromboembolism recurrence rates that argue for anticoagulation therapy
Platelet-predominate gene expression and reticulated platelets in nonvalvular atrial fibrillation: Effect of pulmonary veins isolation( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Ovarian Ve ... to 0.97 for Antithromb ...)

Languages
English (10)